New Zealand markets open in 5 hours 59 minutes

Zhejiang Cheng Yi Pharmaceutical Co., Ltd. (603811.SS)

Shanghai - Shanghai Delayed price. Currency in CNY
Add to watchlist
7.41-0.22 (-2.88%)
At close: 03:00PM CST
Currency in CNY

Valuation measures4

Market cap (intra-day) 2.50B
Enterprise value 2.67B
Trailing P/E 15.90
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)3.66
Price/book (mrq)2.04
Enterprise value/revenue 3.95
Enterprise value/EBITDA 14.46

Trading information

Stock price history

Beta (5Y monthly) 0.41
52-week change 3-43.42%
S&P500 52-week change 323.49%
52-week high 313.71
52-week low 35.78
50-day moving average 37.99
200-day moving average 39.65

Share statistics

Avg vol (3-month) 33.68M
Avg vol (10-day) 32.95M
Shares outstanding 5327.3M
Implied shares outstanding 6327.3M
Float 8191.52M
% held by insiders 138.76%
% held by institutions 115.70%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.25
Forward annual dividend yield 43.28%
Trailing annual dividend rate 30.20
Trailing annual dividend yield 32.62%
5-year average dividend yield 41.67
Payout ratio 452.08%
Dividend date 3N/A
Ex-dividend date 408 Jun 2023
Last split factor 21.4:1
Last split date 308 Jun 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 23.02%
Operating margin (ttm)18.50%

Management effectiveness

Return on assets (ttm)4.07%
Return on equity (ttm)13.15%

Income statement

Revenue (ttm)676.85M
Revenue per share (ttm)2.09
Quarterly revenue growth (yoy)3.50%
Gross profit (ttm)N/A
EBITDA 200.79M
Net income avi to common (ttm)155.83M
Diluted EPS (ttm)0.48
Quarterly earnings growth (yoy)-17.80%

Balance sheet

Total cash (mrq)251.96M
Total cash per share (mrq)0.77
Total debt (mrq)429.48M
Total debt/equity (mrq)34.94%
Current ratio (mrq)1.68
Book value per share (mrq)3.74

Cash flow statement

Operating cash flow (ttm)155.56M
Levered free cash flow (ttm)67.56M